ABSTRACT
Advanced cirrhosis is frequently associated with renal dysfunction. Hepatorenal syndrome (HRS) is characterized by the occurrence of kidney injury in cirrhotic patients in the absence of other identifiable causes. HRS is classified in 2 different types. Type 1 is characterized by acute renal failure and rapid functional deterioration of other organs, usually related to a precipitating event. Type 2 is characterized by slowly progressive renal failure and refractory ascites. Advanced liver disease induces the progression of hemodynamic alterations such as arterial vasodilation of splanchnic circulation and impairment of cardiac function. The resulting ineffective circulating blood volume promotes the activation of both the renin-angiotensin-aldosterone and sympathetic nervous system, by an increase of antidiuretic hormone activity, in an attempt to restore volemia. Despite fluid retention, ascites and dilutional hyponatremia, renal function is often initially preserved by renal production of vasodilators. However, further insults can lead to an imbalance between systemic vasoconstriction and local renal vasodilation, resulting in progressive renal failure. Over the last decade, clinical strategies to prevent HRS have been improved by a better understanding of the natural history of renal failure in cirrhosis, resulting in a reduction of HRS prevalence in cirrhotic patients. Vasoconstrictor drugs may improve renal function, but the effect on mortality has not yet been established. Vaptans, nonpeptide vasopressin receptor antagonists, may also reduce hyponatraemia and ascites, even if the clinical effects in HRS remain unknown. This review updates the pathophysiology, diagnosis and management of HRS.
Subject(s)
Antidiuretic Hormone Receptor Antagonists , Diuretics/therapeutic use , Hepatorenal Syndrome , Vasoconstrictor Agents/therapeutic use , Creatinine/blood , Diuretics/administration & dosage , Diuretics/adverse effects , Dose-Response Relationship, Drug , Hepatorenal Syndrome/diagnosis , Hepatorenal Syndrome/etiology , Hepatorenal Syndrome/therapy , Humans , Hypertension, Portal/complications , Hypertension, Portal/physiopathology , Liver Transplantation , Paracentesis , Portasystemic Shunt, Transjugular Intrahepatic , Renal Circulation/drug effects , Renal Circulation/physiology , Renal Replacement Therapy , Splanchnic Circulation/drug effects , Splanchnic Circulation/physiology , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/physiopathology , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/adverse effects , Vasodilation/drug effectsABSTRACT
Flavonoids, naturally occurring phenolic compounds, have recently been studied extensively for their antioxidant properties. The structure-antioxidant activity relationships (SAR) of flavonoids have been evaluated against different free radicals, but "ferric reducing antioxidant power" (FRAP) assay, which determines directly the reducing capacity of a compound, has not been used for this purpose. In this study, the antioxidant activities of 18 structurally different flavonoids were evaluated by FRAP assay modified to be used in 96-well microplates. Furthermore, their oxidation potentials were also measured, which were in the range of +0.3 V (myricetin) to +1.2 V (5-hydroxy flavone) and were in good agreement with FRAP assay results. Quercetin, fisetin and myricetin had the lowest oxidation potentials and appeared the most active compounds in FRAP assay and were 3.02, 2.52 and 2.28 times more active than Trolox, respectively. Indications were found that the o-dihydroxy structure in the B ring and the 3-hydroxy group and 2,3-double bond in the C ring give the highest contribution to the antioxidant activity.
